National Cancer Institute
dccps logo
Epidemiology and Genetics Research Branch
Cancer Control and Population Sciences


NCI logo  Epidemiology and Genetics Research Program
Division of Cancer Control and Population Sciences
January 31, 2005

EGRP NEWS FLASH
From the Office of
Edward Trapido, Sc.D., Associate Director
Epidemiology and Genetics Research Program
Division of Cancer Control and Population Sciences
National Cancer Institute

This News Flash is to let you know about:

Mukesh Verma, Ph.D.Verma Appointed Acting Chief of Analytic Epidemiology Research Branch

Mukesh Verma, Ph.D., has been named Acting Chief of EGRP's Analytic Epidemiology Research Branch (AERB) with the departure of Sandra Melnick, Dr.P.H. Dr. Melnick has taken a position with the NIH Center for Scientific Review.

Dr. Verma has been the AERB Program Director for the Program Announcement on Small Grants for Cancer Epidemiology and co-Program Director for initiatives in gene-environment interactions, including the Breast and Prostate Cancer and Hormone-Related Variants Cohort Consortium. He will continue his work as Program Director in these areas, and to pursue his interest in developing new initiatives in epigenetics. (See Dr. Verma's article in EGRP Bulletin, Nov. 19, 2004.)

Before joining EGRP in June 2004, Dr. Verma was with NCI's Division of Cancer Prevention (DCP), where he was a Program Director providing direction in the areas of biomarkers, early detection, risk assessment, and prevention. He also was Coordinator of DCP's Small Business Programs (SBIR/STTR Programs). Dr. Verma has developed concepts (Program Announcement (RFA), Request for Applications (RFA)) on exfoliated cells and circulating DNA and their application in cancer detection and risk assessment.

Dr. Verma holds a M.Sc. from Pantnagar University, a Ph.D. in the field of host-virus interaction from Banaras Hindu University, and did postdoctoral research at George Washington University. He also was a faculty member at Georgetown University where he pioneered research in the field of tracheobronchial mucin, which is a glycoprotein that is abnormally expressed in lung cancer. He has published more than 80 research articles in major peer-reviewed journals and has edited two books, Molecular Signatures of Infectious Agents in Cancer and Epigenetics and Cancer Prevention. Dr. Verma also serves on the Editorial Board of Applied Genomics and Proteomics.

His may be reached at tel.: (301) 594-7344; e-mail: vermam@mail.nih.gov.

Two Notices Issued About Delays in Submission of Grant Applications

NIH has published two Notices concerning delays in grant applications. First, grant applications that are submitted late because of January snowstorms should include a cover letter noting the reasons for the delay. It is not necessary to get permission in advance for such weather-related delays in grant application submissions. Delays generally are expected to not exceed the time period that an institution is closed.

The second Notice reviews NIH's overall policy concerning late submission of grant applications. The standing receipt dates are listed in the application kits.

NIH Guide for Grants and Contracts, NOT-OD-05-029 (weather)

NIH Guide, NOT-OD-05-030 (overall policy)

NIH Director's Pioneer Award Program Seeks Nominations

NIH has announced plans to accept nominations for the 2005 NIH Director's Pioneer Award between March 1 and April 1.

"The Pioneer Award supports scientists of exceptional creativity who take innovative approaches to major challenges in biomedical research," said NIH Director Elias A. Zerhouni, M.D., in the announcement. "We look forward to adding a new cohort of visionary thinkers to the outstanding group of scientists chosen in the first year of this program."

Unlike other NIH grants, which support research projects, the Pioneer Award supports individual scientists. The award gives recipients the intellectual freedom to pursue new research directions and highly innovative ideas that have the potential for unusually great impact.

In September 2005, NIH expects to make five to 10 new Pioneer Awards of up to $500,000 in direct costs per year for five years.

The self-nomination process includes a 3- to 5-page essay, a biographical sketch, list of current research support, and names of three references. Submit applications on the Pioneer Award Web site.

NIH Guide, NOT-OD-05-021

Solicitation for 2005 Announced for Small Business Grants

The Solicitation for the Small Business Innovation Research and Small Business Technology Transfer Research (STTR) Programs for 2005 is now available. These programs are to support innovative research with potential for commercialization. In the SBIR Program, funding is usually provided for up to six months and $100,000 total cost for Phase I feasibility studies, and for up to two years and $750,000 for Phase II projects.

The STTR Program requires close collaboration between the small business and a partnered research institution. The small business is to conduct at least 40% of the research project, and the single, partner institution conducts at least 30% of the work. Funding is usually provided for up to one year and $100,000 total cost for Phase I feasibility studies, and for up to two years and $750,000 for Phase II projects.

The SBIR and STTR legislation requires that the Public Health Service (PHS), Department of Health and Human Services, and certain other federal agencies reserve 2.5% of their extramural research/research and development budgets for an SBIR Program and 0.3% of their extramural research/research and development budgets for an STTR Program. The PHS SBIR and STTR set-aside requirements for FY 2005 are estimated to be $630 million.

The solicitation and application forms are available through the NIH Small Business Funding Opportunities Web site.

Following are topics relevant to cancer epidemiology that EGRP is interested in supporting:

  1. Development of Web-based data collection tools or applicable
    bioinformatics for translational research in cancer.
  2. Development of software or methods for rapid case ascertainment for
    cancers.
  3. Development of software for allowing biological specimens for
    genetic and molecular testing of cancer.
  4. Conversion, validation, and documentation of statistical software
    packages for use in genetic and general epidemiological analyses on microcomputers.
  5. Methods for the detection of biological markers of human exposure,
    human susceptibility, or nutritional status for use in epidemiological studies.
  6. Development of banks of standard questions about cancer risk
    factors, suitably referenced for prior use, validity, reliability, and with appropriate evaluation of index questions. The resource should accommodate either interviewer- or self-administered approaches with flexibility to accommodate requests of varying informational depth.
  7. Development of geographic information systems with special
    visualization techniques for the simultaneous assessment of environmental exposures and health outcomes.
  8. Improvements in computer-assisted telephone interviewing technology.
    Such improvements should permit refinements such as branching, rechecking of previous responses, tallies or summaries of the sum of specific responses for comparison with response to a more general question, and the entry of text as well as codes.
  9. Development of an improved indexing system for epidemiological
    literature and for data banks listing research in progress.
  10. Development of molecular genetic techniques/methods applicable to
    large-scale epidemiological studies.
  11. Development and maintenance of a repository for unreported data on
    molecular/genetic polymorphisms.
  12. Development of educational intervention software packages for women
    and minorities exposed to occupational carcinogens.

The EGRP Program Director is Jay Choudhry, M.S., e-mail: choudhrj@mail.nih.gov.

NIH Guide, NOT-OD-05-027

NIH Funding and Grants Administration Seminars Set for New Mexico and Indiana

Two regional seminars covering topics related to NIH extramural program funding and grants administration will be held this year. These seminars are for research administrators, researchers new to NIH, post docs, and trainees. Opportunities for informal interactions between seminar participants and NIH grants management, program, policy, and review staff are incorporated into the programs. On the preceding Wednesday of each of the seminars there will be NIH electronic research administration labs. The seminar and lab dates are:

  • April 7-8, 2005, hosted by the University of New Mexico,
    Albuquerque, N.M. NIH electronic research administration (eRA) labs will be offered on Wed., April 6.
  • June 23-24, 2005, hosted by Purdue University, West Lafayette,
    Indiana. NIH electronic research administration (eRA) labs will be offered on Wed., June 22.

For information on the programs and logistics, access the NIH Office of Extramural Research regional seminar Web site.

Direct questions about registration or logistics to the host universities, and questions on the program content to Ms. Megan Columbus, NIH Regional Seminar Coordinator, tel.: (301) 435-0937; e-mail: megan.columbus@nih.gov.

NIH Guide, NOT-OD-05-019

Revisions Made to PHS 398 Human Subjects Research Supplement

Significant revisions have been made in the PHS 398, Part II, Human Subjects Research Supplement, to address NIH implementation of Office for Human Research Protections (OHRP) guidance on research involving coded private information or biological specimens. Notable changes in content appear in purple lettering in the PHS 398 Supplemental Instructions for Preparing the Human Subjects Section of the Research Plan.

All new and competing continuation grant applications and non-competing grant progress reports (Type 5) involving coded private information or biological specimens submitted to NIH on or after January 10, 2005, should follow the revised instructions outlined in the PHS 398. Although use of the September 2004 version of the PHS 398 is not mandatory until May 10, 2005, the new version includes detailed instructions to help applicants apply the OHRP guidance. To minimize confusion in preparation of applications, applicants are urged to use the new version for applications impacted by this guidance.

NIH Grants Forms

NIH Guide, NOT-OD-05-20

Newly Revised PHS 398 Announced November 2004 (EGRP Bulletin)

Reminder to Identify Small Grant (R03) and Exploratory Grant (R21) Applications on PHS 398 Forms

Please remember to specify in your grant application materials if you are submitting a small grant (R03) or exploratory/developmental research grant (R21) application. (The information is to appear on line 2 of the PHS 398.) This reminder and related information on submitting R03 and R21 applications appears in the NIH Guide, NOT-OD-05-010.

Although the Notice is specific to R21s and R03s, it is always important to reference the relevant Program Announcement (PA/PAR). We'll use this opportunity to remind investigators that EGRP sponsors a PA for Small Grants Program for Cancer Epidemiology (R03). Applications are invited relating to cancer epidemiology with a primary focus on etiologic cancer research. These short-term awards provide support for pilot projects, testing of new techniques, or development of innovative projects that could provide a basis for more extended research. Access the PA for examples and other information:

The EGRP Program Director is Mukesh Verma, Ph.D., Acting Chief, AERB;
e-mail: vermam@mail.nih.gov.

International Cancer Research Portfolio Database Available on Web

The International Cancer Research Portfolio is a relational database made available through the Web that provides current information on cancer research funded by members of the International Cancer Research Partners. The member organizations are from the United States, including NCI, Department of Defense, and American Cancer Society, and from the United Kingdom. The database can be searched and sorted by a variety of data fields. Access the Web site.

Also, following are links to two other online research portfolio databases mentioned in earlier News Flashes:

Review of Funding Opportunities Funded By EGRP

Following is a list of the funding opportunities currently sponsored or cosponsored by EGRP:

  • Studies of Energy Balance and Cancer in Humans (R01, R21,
    competitive supplements to existing NCI-funded grants) (PA-04-124)
  • Exfoliated Cells, Bioactive Food Components, and Cancer (R01, R21, R03) (PA-04-114)
  • Occupational Safety and Health Research (R01) (PA04-038)
  • Cohort Studies in Cancer Epidemiology (R01) (PAR-04-011). Also accesse additional policy (NOT-CA-04-001).
  • Research on Malignancies in AIDS and Acquired Immune Suppression
    (R01, R21) (PA-04-157)
  • Small Grants Program for Cancer Epidemiology (R03) (PAR 03-010) (Effective now). PAR effective beginning with November 21, 2005, receipt date (PAR 04-159).
  • Small Business Grants (SBIR and STTR Programs)

You are welcome to invite others to subscribe to receive occasional Bulletins and News Flashes from the Epidemiology and Genetics Research Program (EGRP). To subscribe to FRIENDS-OF-NCI-EGRP-L, contact andersL2@mail.nih.gov.


Last modified:
28 Oct 2008
Search | Contact Us | Accessibility | Privacy Policy
  DCCPS National Cancer Institute Department of Health and Human Services National Institutes of Health USA.gov: The US government's official web portal